NRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-8.08 Insider Own59.40% Shs Outstand57.80M Perf Week0.74%
Market Cap83.76M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float35.14M Perf Month-43.80%
Income-348.90M PEG- EPS next Q- Inst Own14.20% Short Float7.34% Perf Quarter-54.82%
Sales- P/S- EPS this Y- Inst Trans248.19% Short Ratio4.28 Perf Half Y-78.14%
Book/sh0.36 P/B3.78 EPS next Y- ROA- Target Price- Perf Year-93.44%
Cash/sh0.45 P/C3.03 EPS next 5Y- ROE- 52W Range1.15 - 48.80 Perf YTD-71.55%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-97.21% Beta0.75
Dividend %- Quick Ratio2.70 Sales past 5Y- Gross Margin- 52W Low18.26% ATR0.17
Employees2 Current Ratio2.70 Sales Q/Q- Oper. Margin- RSI (14)34.00 Volatility12.31% 11.32%
OptionableYes Debt/Eq0.02 EPS Q/Q-31.70% Profit Margin- Rel Volume0.68 Prev Close1.32
ShortableYes LT Debt/Eq0.00 EarningsMay 16 BMO Payout- Avg Volume603.20K Price1.36
Recom- SMA20-16.90% SMA50-40.30% SMA200-78.99% Volume453,136 Change3.03%
May-16-22 07:12AM  
May-12-22 08:17AM  
May-10-22 08:11AM  
Apr-21-22 08:48AM  
Apr-08-22 08:57AM  
Mar-31-22 08:17AM  
Mar-28-22 03:17AM  
Mar-18-22 05:00AM  
Mar-09-22 01:25PM  
Mar-08-22 10:25PM  
Feb-21-22 07:21AM  
Feb-15-22 08:32AM  
Feb-11-22 08:01AM  
Feb-02-22 07:06PM  
Jan-31-22 07:59AM  
Jan-27-22 06:51AM  
Jan-26-22 06:51AM  
Jan-20-22 08:28PM  
Jan-18-22 06:48AM  
Jan-14-22 03:12PM  
Jan-12-22 05:48PM  
Jan-11-22 07:54AM  
Jan-07-22 05:50PM  
Jan-05-22 10:14AM  
Jan-03-22 07:16AM  
Dec-29-21 06:48AM  
Dec-19-21 06:38AM  
Dec-15-21 06:48AM  
Dec-14-21 06:48AM  
Dec-09-21 09:21AM  
Dec-06-21 09:07AM  
Nov-29-21 01:57PM  
Nov-26-21 10:06AM  
Nov-16-21 05:56AM  
Nov-12-21 11:46AM  
Nov-11-21 07:54AM  
Nov-09-21 05:25PM  
Nov-08-21 12:58PM  
Nov-05-21 05:45PM  
Nov-04-21 06:08PM  
Nov-02-21 11:04AM  
Oct-14-21 06:48AM  
Oct-12-21 06:48AM  
Sep-29-21 06:48AM  
Sep-27-21 07:04AM  
Sep-08-21 07:48AM  
Aug-30-21 08:06AM  
Aug-26-21 06:48AM  
Aug-25-21 09:43AM  
Aug-24-21 06:48AM  
Aug-23-21 09:33AM  
Aug-19-21 09:17AM  
Aug-18-21 11:53AM  
Aug-16-21 09:32PM  
Aug-11-21 04:20PM  
Aug-10-21 06:48AM  
Aug-09-21 01:13PM  
Aug-04-21 06:48AM  
Jul-27-21 11:34AM  
Jul-22-21 06:48AM  
Jul-19-21 06:48AM  
Jul-12-21 11:18AM  
Jul-06-21 09:20AM  
Jun-15-21 07:33AM  
Jun-09-21 02:50PM  
Jun-08-21 02:03PM  
Jun-07-21 01:45PM  
Jun-01-21 06:28AM  
May-27-21 06:48AM  
May-26-21 09:29AM  
NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Besthof RobertChief Comm. & Patient OfficerSep 15Sale11.7640,000470,40023,710Nov 02 04:04 PM
Daigneault AlessandraGeneral Counsel & SecretarySep 02Option Exercise3.0731,58496,96331,584Nov 02 04:05 PM
McMaster Herbert RaymondDirectorAug 26Option Exercise2.2218,30040,62618,300Nov 02 04:07 PM
Daigneault AlessandraGeneral Counsel & SecretaryAug 23Sale13.1133,715442,0040Nov 02 04:05 PM
Daigneault AlessandraGeneral Counsel & SecretaryAug 19Option Exercise3.0727,39584,10333,715Nov 02 04:05 PM
Besthof RobertChief Comm. & Patient OfficerAug 16Option Exercise0.2063,71012,74263,710Nov 02 04:04 PM